RxDoctor Payments Data

James Pappas, MD

Neurology with Special Qualifications in Child Neurology · Indianapolis, INNPI 1710928148

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by UCB, Inc. at 26.2% of the total. Reporting peaked in 2019 at $543 and has fallen 88.4% since, to $63 in 2025.

$780in general payments, 2019–2025

Across 49 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$205
  • Sunovion Pharmaceuticals Inc.$80
  • Livanova USA, Inc.$72
  • Aquestive Therapeutics, Inc.$61
  • Supernus Pharmaceuticals, Inc.$58
  • Upsher-smith Laboratories LLC$56
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$76898%
  • Education$132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780 in reported general payments places this provider in the 55th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

See all neurology with special qualifications in child neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$3,623
Medicare patients
20
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate18$51,297
XcopriCenobamate31$38,545
FycompaPerampanel12$14,295
LamictalLamotrigine23$11,499
Felbamate29$10,261
Clobazam46$9,752
Lamotrigine OdtLamotrigine24$8,700
Oxcarbazepine39$6,551
Topiramate ErTopiramate11$4,703
Lacosamide43$3,451
Levocarnitine20$2,517
Levetiracetam54$2,293
Phenobarbital22$1,914
Zonisamide21$1,362
Diazepam11$1,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$80$51,29718 claims
SK Life Science, Inc.Xcopri$26$38,54531 claims
Eisai Inc.Fycompa$34$14,29512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 neurology with special qualifications in child neurology providers in Indiana.

Other neurology with special qualifications in child neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →